This report examines selected AI-based initiatives, collaborations, and tests in various in vitro diagnostic (IVD) market segments.
Artificial Intelligence Markets in IVD contains the following important data points:
The Market for AI in Diagnostics, 2019
Forecasted Market for 2024
Breakout of Market by Application, 2019 (Glucose, Histology, Microbiology, Hematology, Biomarker Diagnostic Aids)
Breakout of Market by Components, 2019 (Hardware, Software, Services)
Significant Partnerships and Initiatives in AI Related to In Vitro Diagnostics
The past few years have seen extraordinary advances in artificial intelligence (AI) in clinical medicine. More products have been cleared for clinical use, more new research-use-only applications have come to market and many more are in development.
In recent years, diagnostics companies - in collaboration with AI companies - have begun implementing increasingly sophisticated machine learning techniques to improve the power of data analysis for patient care. The goal is to use developed algorithms to standardize and aid interpretation of test data by any medical professional irrespective of expertise. This way AI technology can assist pathologists, laboratorians, and clinicians in complex decision-making.
Digital pathology products and diabetes management devices were the first to come to market with data interpretation applications. The last few years have seen the use of AI interpretation apps extended to a broader range of products including microbiology, disease genetics, and cancer precision medicine.
This report will review some of the AI-linked tests and test services that have come to market and others that are in development in some of the following market segments:
Cardiac Disease Testing
Information Technology (including Electronic Medical Records)
Point of Care
Transplant Risk Testing
Applications of AI are evolving that predict outcomes such as diagnosis, death, or hospital readmission; that improve upon standard risk assessment tools; that elucidate factors that contribute to disease progression; or that advance personalized medicine by predicting a patient's response to treatment. AI tools are in use and in development to review data and to uncover patterns in the data that can be used to improve analyses and uncover inefficiencies. Many enterprises are joining this effort.
The following are among the companies and institutions whose innovations are featured in Artificial Intelligence Markets in IVD:
Bay Echo Labs
Biofourmis Singapore Pte. Ltd.
Caris Life Sciences
Case Western Reserve University
Clever Culture Systems
Gnosis Data Analysis
IBM Watson Health
Rady Children's Institute for Genomic Medicine
Reliant Immune Diagnostics
Key Topics Covered
Chapter 1: Executive Summary
The Artificial Intelligence Boom
The FDA Is Getting Ready
FDA Awards DNAnexus Contract to Power precision FDA Collaborative Omics Environment in the Cloud
COVID-19 and Artificial Intelligence
Deep Learning to Discover Origins of COVID-19
AI-Assisted App Will Direct Individuals Most At Risk for Having COVID-19
FDA Allows Remote Use of Philips IntelliSite Pathology Solution during COVID Crisis
JLK Inspection: RT-PCR COVID-19 Testing with AI-Enhanced Imaging Aid
Persivia: Ruleset to Triage COVID-19 Testing
Surgisphere Rapid Test Uses AI to Diagnose COVID-19
Biofourmis' AI-Powered Remote Monitoring Platform to Fight COVID-19
Chapter 2: Artificial Intelligence In Diagnostics Markets